Valuation: Clene Inc.

Market Cap 68.88M 60.55M 56.36M 51.76M 97.2M 6.61B 98.48M 670M 262M 3.26B 259M 253M 11.27B P/E 2026 *
-3.02x
P/E 2027 * -3.66x
Enterprise Value 55.48M 48.77M 45.4M 41.69M 78.29M 5.32B 79.32M 540M 211M 2.63B 208M 204M 9.08B EV / Sales 2026 *
267x
EV / Sales 2027 * 2.01x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-5.76%
Current month-12.27%
1 month-14.76%
3 months-10.89%
6 months+4.05%
Current year-8.01%
1 week 5.29
Extreme 5.29
5.96
1 month 5.29
Extreme 5.29
6.55
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
15.8
5 years 2.28
Extreme 2.2801
196.8
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
11/6/26 Free

Founder

45,000 0.3522%
11/6/26 Free

Chief Financial Officer

15,000 0.1174%
11/6/26 Free

Chief Executive Officer

65,000 0.5087%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-5.76%+58.82%-63.11% 68.88M
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-1.09%-1.21%+3.90%+418.24% 23.18B
+2.86%-0.39%-18.61%-12.57% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.31%+0.95%+26.29%+186.02% 13.92B
Average +0.69%+0.56%+43.88%+153.78% 24.02B
Weighted average by Cap. +0.07%+1.93%+39.94%+138.68%

Financials

2026 *2027 *
Net sales 207K 182K 170K 156K 293K 19.89M 297K 2.02M 788K 9.82M 779K 762K 33.94M 23.64M 20.79M 19.35M 17.77M 33.37M 2.27B 33.81M 230M 89.82M 1.12B 88.76M 86.85M 3.87B
Net income -25.09M -22.06M -20.53M -18.86M -35.41M -2.41B -35.88M -244M -95.33M -1.19B -94.2M -92.17M -4.11B -27.55M -24.22M -22.54M -20.7M -38.88M -2.64B -39.39M -268M -105M -1.3B -103M -101M -4.51B
Net Debt -13.4M -11.78M -10.97M -10.07M -18.91M -1.29B -19.16M -130M -50.91M -635M -50.3M -49.22M -2.19B -21.4M -18.81M -17.51M -16.08M -30.2M -2.05B -30.6M -208M -81.3M -1.01B -80.33M -78.6M -3.5B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
28/07/26 US$5.400 +0.19% 23,697
24/07/26 US$5.390 -1.64% 48,257
23/07/26 US$5.480 -5.84% 85,518
22/07/26 US$5.820 -0.51% 42,792
21/07/26 US$5.850 +2.09% 72,499
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.390USD
Average target price
32.20USD
Spread / Average Target
+497.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock